Sarepta Therapeutics Inc  

(Public, NASDAQ:SRPT)   Watch this stock  
Find more results for NASDAQ:AVII
26.74
+0.03 (0.11%)
Real-time:   10:26AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 26.18 - 27.00
52 week 11.33 - 35.43
Open 26.56
Vol / Avg. 284,501.00/2.01M
Mkt cap 1.11B
P/E     -
Div/yield     -
EPS -4.13
Shares 41.47M
Beta 0.91
Inst. own 60%
Aug 5, 2015
Q2 2015 Sarepta Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 2, 2015
Sarepta Therapeutics Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
May 7, 2015
Q1 2015 Sarepta Therapeutics Inc Earnings Release
May 7, 2015
Q1 2015 Sarepta Therapeutics Inc Earnings Call - Webcast
Apr 1, 2015
Sarepta Therapeutics Inc. Appoints Edward Kaye, M.D., as Interim CEO and Management Update Conference Call - Webcast
Mar 12, 2015
Sarepta Therapeutics Inc at Barclays Healthcare Conference - Webcast
Mar 9, 2015
Sarepta Therapeutics Inc at ROTH Conference
Mar 2, 2015
Sarepta Therapeutics Inc at Cowen Health Care Conference - Webcast
Feb 26, 2015
Q4 2014 Sarepta Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -1391.71%
Operating margin - -1371.21%
EBITD margin - -1313.34%
Return on average assets -91.83% -46.30%
Return on average equity -110.13% -54.88%
Employees 204 -
CDP Score - -

Address

SUITE 415, 215 FIRST STREET
CAMBRIDGE, MA 02142
United States - Map
+1-617-2744000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Sarepta Therapeutics Inc. (Sarepta), formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company has classified its drug development programs as Duchenne Muscular Dystrophy (DMD) and Infectious Disease Programs. The Company’s Duchenne muscular dystrophy (DMD) is primarily focused on its lead product candidate, Eteplirsen. The Company has completed a Phase IIb clinical trial for Eteplirsen. The Company, under its infectious disease programs, is primarily focused on development of a drug candidate for the Marburg hemorrhagic fever virus. The Company’s infectious disease programs is largely funded and supported by the U.S. Department of Defense (DoD).

Officers and directors

Edward M. Kaye M.D. Interim Chief Executive Officer, Senior Vice President, Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Sandesh Mahatme Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
David Tyronne Howton Senior Vice President, General Counsel, Corporate Secretary
Age: 43
Bio & Compensation  - Reuters
Jayant Aphale Ph.D. Senior Vice President - Technical Operations
Age: 54
Bio & Compensation  - Reuters
M. Kathleen Behrens Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Anthony R. Chase Independent Director
Age: 60
Bio & Compensation  - Reuters
Gil Price M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Hans Wigzell M.D., Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
William A. Goolsbee Non-Executive Independent Director
Age: 61
Bio & Compensation  - Reuters